Tag: Immunogen
Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for...
Creating A Strong ADC Pipeline: AbbVie Agrees to Acquires ImmunoGen for $10.1 Billion
Immunogen’s Mirvetuximab Soravtansine-gynx Sales Projected to Reach US $ 615 Million...
On November 14, 2022 the US Food and Drug Administration (FDA) granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic treatment regimens.
Mirvetuximab Soravtansine Demonstrates Overall Survival Benefit in FRα-Positive Platinum-Resistant Ovarian Cancer
Positive top-line data from the Phase 3 confirmatory MIRASOL trial (NCT04209855; GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of mirvetuximab soravtansine-gynx compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
FDA Approves Mirvetuximab Soravtansine-gynx for FRα+ Platinum-resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere®; ImmunoGen), previously known as IMGN853, for the treatment of patients diagnosed...
Huadong Medicine and ImmunoGen Sign Strategic Agreement to Develop and Commercialize...
ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., a wholly-owned subsidiary of Huadong Medicine Co., Chinese pharmaceutical company founded in 1993, have entered into an...
Susan Altschuller, Ph.D. Appointed as ImmunoGen’s Senior Vice President and Chief...
ImmunoGen announced that Susan Altschuller, Ph.D. has been appointed as the company's Senior Vice President and Chief Financial Officer.
“Susan is an outstanding addition to...
Confirmatory Study of Mirvetuximab Soravtansine in Ovarian Cancer on Track to...
In a statement earlier today, ImmunoGen confirmed that the U.S. Food and Drug Administration (FDA) has advised that a new single-arm study in platinum-resistant...
ImmunoGen to Prioritize Continued Development of Mirvetuximab Soravtansine
Waltham, Massachusetts, based ImmunoGen, expanding field of antibody-drug conjugates (ADCs) with the development of the next generation of targeted anti-cancer agents, has completed an...
ImmunoGen and FDA Discuss Ongoing Development for Mirvetuximab Soravtansine
The United States Food and Drug Administration (FDA) has recommended that ImmunoGen conducts a new Phase III randomized trial to evaluate the safety and...
Speaker’s Perspective on World ADC San Diego 2018
We caught up with two of the speakers presenting at this year's World ADC and asked, "What are you looking forward to at this...
